Takeda Pharmaceutical Co Ltd - Form 6-K Summary
Business Context and Reporting Period
This filing is a Form 6-K reporting the Quarterly Securities Report for the nine-month period ended December 31, 2021 (FY2021 Q3 YTD). Takeda is a global biopharmaceutical company focused on gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. The report was filed with the Kanto Local Finance Bureau in Japan on February 10, 2022.
Key Financial Metrics
| Metric (Nine Months Ended Dec 31, 2021) | Value (JPY Billion) | YoY Change |
|---|---|---|
| Revenue | 2,695.7 | +11.0% |
| Operating Profit | 462.5 | +28.9% |
| Profit Before Tax | 356.6 | +51.5% |
| Net Profit for the Period | 241.5 | +34.9% |
| Net Profit Attributable to Owners | 241.4 | +34.9% |
| Basic EPS | 154.09 JPY | +34.5% |
| Operating Cash Flow | 747.5 | +22.5% |
| Cash and Cash Equivalents (End of Period) | 724.3 | -24.9% vs FY2020 |
| Total Assets | 12,698.5 | -1.7% vs FY2021 YE |
| Total Liabilities | 7,366.7 | -4.8% vs FY2021 YE |
| Bonds and Loans | 4,354.9 | -6.1% vs FY2021 YE |
Non-IFRS Metrics: Underlying Revenue Growth was +7.1%. Underlying Core Operating Profit Growth was +5.4% with a margin of 29.4%. Underlying Core EPS Growth was +9.9%.
Material Changes vs. Prior Period
- Revenue Growth: Driven by an 11.0% increase, partially due to a one-time 133.0 billion JPY gain from the sale of a diabetes portfolio in Japan. Excluding this and FX effects, organic growth was 5.6%.
- Profitability: Operating profit rose 28.9% to 462.5 billion JPY. This was aided by a decrease in Other Operating Expenses (down 35.5%) due to lower restructuring costs and a decrease in Net Finance Expenses (down 12.8%) from debt repayments.
- Tax Impact: Income tax expenses increased 104.3% to 115.1 billion JPY, primarily due to a 64.6 billion JPY tax charge related to an Irish tax assessment on a break fee from the terminated AbbVie-Shire acquisition.
- Therapeutic Areas:
- GI: +13.1% (driven by ENTYVIO +23.8%).
- Rare Diseases: +3.6% (Rare Metabolic +9.5%, Rare Hematology -3.2%).
- PDT Immunology: +16.0% (Albumin sales +41.0%).
- Oncology: +12.8% (VELCADE +11.3%, ADCETRIS +16.7%).
- Neuroscience: +15.1% (VYVANSE/ELVANSE +21.0%).
- Balance Sheet: Bonds and loans decreased by 280.5 billion JPY due to significant debt prepayments (including 3.7 billion USD of JBIC loans and various senior notes).
Guidance, Outlook, Risks, and Unusual Items
- Unusual Items:
- Divestiture Gain: 133.0 billion JPY recorded from the sale of the Japan diabetes portfolio to Teijin Pharma.
- Tax Charge: 64.6 billion JPY provision for Irish tax assessment on the AbbVie break fee.
- Other Operating Income: Decreased 71.1% due to the absence of a 60.2 billion JPY revaluation gain from the prior year related to the SHP647 pipeline compound.
- R&D Updates:
- Approvals: LIVTENCITY (CMV) approved in the U.S.; EXKIVITY (NSCLC) approved in the U.S.; ENTYVIO approved for chronic pouchitis in the EU; VONVENDI approved for prophylaxis in the U.S.
- Discontinuations: TAK-994 (narcolepsy) Phase 2 studies suspended due to a safety signal; TAK-721 (eosinophilic esophagitis) program discontinued after FDA Complete Response Letter.
- Failures: Phase 3 PANTHER study for pevonedistat (TAK-924) did not meet primary endpoint; CoVIg-19 (anti-coronavirus immunoglobulin) Phase 3 trial did not meet endpoints.
- Outlook & Risks: Management states no significant change in risk factors. COVID-19 has not had a material effect on financials, though some Neuroscience products faced temporary headwinds. The Omicron variant has not caused material disruption. Takeda continues to distribute Moderna and Novavax vaccines in Japan.
- Subsequent Events: On January 28, 2022, Takeda notified holders of 1.5 billion USD senior notes of redemption in March 2022.
Key Facts for Investor Verification
- Quality of Earnings: Verify the sustainability of revenue growth by excluding the 133.0 billion JPY one-time diabetes portfolio sale (Underlying growth is 7.1%).
- Tax Liability: Confirm the status of the 64.6 billion JPY Irish tax charge and the ongoing appeal process regarding the AbbVie break fee.
- Debt Reduction: Note the aggressive deleveraging strategy with 280.5 billion JPY in debt repayments during the period, improving liquidity but reducing cash reserves.
- R&D Pipeline Risk: Monitor the impact of the TAK-994 safety signal suspension and the TAK-721 discontinuation on future Neuroscience growth projections.
- Divestitures: Track the completion of the China non-core prescription pharmaceutical divestiture, expected in the second half of FY2021.